이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Rigel Pharmaceuticals 관리

관리 기준 확인 2/4

Rigel Pharmaceuticals' CEO는 Raul Rodriguez, May2010 에 임명되었습니다 의 임기는 14.08 년입니다. 총 연간 보상은 $ 3.44M, 21.2% 로 구성됩니다. 21.2% 급여 및 78.8% 보너스(회사 주식 및 옵션 포함). 는 $ 1.18M 가치에 해당하는 회사 주식의 0.75% 직접 소유합니다. 1.18M. 경영진과 이사회의 평균 재임 기간은 각각 3.1 년과 6.6 년입니다.

주요 정보

Raul Rodriguez

최고 경영자

US$3.4m

총 보상

CEO 급여 비율	21.2%
CEO 임기	14.1yrs
CEO 소유권	0.7%
경영진 평균 재임 기간	3.1yrs
이사회 평균 재임 기간	6.6yrs

최근 관리 업데이트

Recent updates

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15

What Does The Future Hold For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)? These Analysts Have Been Cutting Their Estimates

Mar 06

Rigel PharmaceuticalsA Biopharma With A Free Shot On Goal In COVID-19, With A Pipeline As A Safety Net

Feb 01

An Intrinsic Calculation For Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Suggests It's 26% Undervalued

Jan 14

Rigel Pharmaceuticals: New Omicron Variant Keeps Tavalisse Treatment Prospects Alive

Nov 30

Is Rigel Pharmaceuticals (NASDAQ:RIGL) Using Debt In A Risky Way?

Nov 02

Rigel Pharma: Positive Data Supports Use Of Tavalisse In COVID-19 As Variants Subterfuge Vaccines

Sep 06

CEO 보상 분석

Raul Rodriguez 의 보수는 Rigel Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$20m
Dec 31 2023	US$3m	US$728k	-US$25m
Sep 30 2023	n/a	n/a	-US$24m
Jun 30 2023	n/a	n/a	-US$38m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$3m	US$700k	-US$59m
Sep 30 2022	n/a	n/a	-US$83m
Jun 30 2022	n/a	n/a	-US$85m
Mar 31 2022	n/a	n/a	-US$85m
Dec 31 2021	US$3m	US$662k	-US$18m
Sep 30 2021	n/a	n/a	-US$15m
Jun 30 2021	n/a	n/a	-US$8m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$3m	US$662k	-US$30m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$25m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$3m	US$649k	-US$67m
Sep 30 2019	n/a	n/a	-US$46m
Jun 30 2019	n/a	n/a	-US$59m
Mar 31 2019	n/a	n/a	-US$64m
Dec 31 2018	US$4m	US$637k	-US$70m
Sep 30 2018	n/a	n/a	-US$100m
Jun 30 2018	n/a	n/a	-US$93m
Mar 31 2018	n/a	n/a	-US$87m
Dec 31 2017	US$2m	US$618k	-US$78m

보상 대 시장: Raul 의 총 보상 ($USD 3.44M )은 US 시장( $USD 1.62M ).

보상과 수익: 회사가 수익성이 없는 동안 Raul 의 보상이 증가했습니다.

CEO

Raul Rodriguez (63 yo)

14.1yrs

테뉴어

US$3,440,790

보상

Mr. Raul R. Rodriguez has been the Chief Executive Officer and Director of Rigel Pharmaceuticals, Inc., since November 2014 and its President since May 2010. Mr. Rodriguez served as Chief Operating Officer...

리더십 팀

이름	위치	테뉴어	보상	소유권
Raul Rodriguez	President	14.1yrs	US$3.44m	0.75% $ 1.3m
Dean Schorno	Executive VP & CFO	6.1yrs	US$1.21m	0.069% $ 116.0k
Raymond Furey	Executive VP	1.5yrs	US$683.00k	0.0029% $ 4.8k
David Santos	Executive VP & Chief Commercial Officer	3.8yrs	US$1.34m	0.031% $ 52.6k
Julie Patel	Senior VP of Human Resources	2.4yrs	데이터 없음	데이터 없음
Esteban Masuda	Executive Vice President of Research	7.8yrs	US$796.09k	데이터 없음
Joseph Lasaga	Executive VP & Chief Business Officer	less than a year	데이터 없음	데이터 없음
Lisa Rojkjaer	Executive VP & Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Tarek Sallam	Vice President of Marketing	no data	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 관리: RIGL 의 관리팀은 경험 ( 3.1 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Raul Rodriguez	President	9.6yrs	US$3.44m	0.75% $ 1.3m
Walter Moos	Independent Director	27.3yrs	US$138.58k	0.044% $ 73.7k
Brian Kotzin	Independent Director	6.8yrs	US$138.58k	0.043% $ 71.6k
Jane Wasman	Independent Director	5.3yrs	US$145.58k	0.043% $ 71.6k
Gregory Lapointe	Independent Chairman of the Board	6.6yrs	US$190.58k	0.043% $ 71.6k
Kamil Ali-Jackson	Independent Director	2.5yrs	US$140.58k	0.025% $ 41.7k
Alison Hannah	Independent Director	3.1yrs	US$212.98k	0.032% $ 53.7k

6.6yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: RIGL 의 이사회는 경험(평균 재직 기간 6.6 년)으로 간주됩니다.

Rigel Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer

President recently sold US$60k worth of stock

Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023

President recently bought US$688k worth of stock

Recent updates

Price target increased by 44% to US$65.33

Consensus EPS estimates upgraded to US$0.65 loss

Rigel Pharmaceuticals Completes Transfer of GAVRETO®? (pralsetinib) New Drug Application

Rigel Pharmaceuticals, Inc. Announces Five Presentations at the EHA2024 Hybrid Congress

Insufficient new directors

Consensus EPS estimates upgraded to US$0.062 loss

Consensus EPS estimates upgraded to US$0.073 loss

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Price target increased by 14% to US$5.08

Rigel Pharmaceuticals, Inc., Annual General Meeting, May 22, 2024

Consensus EPS estimates fall by 13%

Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer as Chief Medical Officer

Consensus estimates of losses per share improve by 12%

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Forecast breakeven date moved forward to 2025

Price target increased by 10% to US$4.46

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

President recently sold US$60k worth of stock

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

No longer forecast to breakeven

New minor risk - Share price stability

Forecast to breakeven in 2025

Rigel Pharmaceuticals, Inc. Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Consensus EPS estimates upgraded to US$0.19 loss

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Poster Presentations At the 65Th American Society of Hematology Annual Meeting and Exposition

Rigel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from the Focus Phase 3 Clinical Trial of Fostamatinib in Hospitalized COVID-19 Patients and Provides Update on ACTIV-4 Host Tissue Trial

Consensus EPS estimates upgraded to US$0.25 loss

New minor risk - Profitability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rigel Pharmaceuticals, Inc. Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

Rigel Pharmaceuticals, Inc. Announces Second -2-2-Appointment of Olutasidenib as Therapeutics

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Price target increased by 7.6% to US$3.85

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rigel Pharmaceuticals, Inc. Announces Resignation of Wolfgang Dummer as Executive Vice President and Chief Medical Officer, Effective March 31, 2023

Rigel Pharmaceuticals, Inc. Announces Publication of REZLIDHIA (Olutasidenib) Phase 2 Clinical Results in Blood Advances

National Comprehensive Cancer Network Adds Newly Approved Rigel Pharmaceuticals, Inc.'s REZLIDHIA™ (Olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia

Price target increased to US$4.11

Rigel Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

Rigel Pharmaceuticals, Inc. Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals, Inc. Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes

Rigel Pharmaceuticals, Inc. Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

Rigel Pharmaceuticals Received a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Rigel Pharmaceuticals, Inc. Announces Publication of Early Clinical Data of Olutasidenib in the Lancet Haematology

Third quarter 2022 earnings: EPS exceeds analyst expectations

Rigel Pharmaceuticals, Inc. Announces Top-Line Results from Focus Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized Covid-19 Patients

Rigel Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Now 22% undervalued after recent price drop

Rigel Pharmaceuticals, Inc. Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback

Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib

Now 21% undervalued

Price target decreased to US$2.08

Rigel Pharma adds ~7% to reach over two month high

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Rigel rises 17% on strong Q2 result

Rigel Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 02, 2022

President recently bought US$688k worth of stock

Rigel Pharmaceuticals, Inc. Announces Top-Line Results from Forward Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia

Rigel Pharmaceuticals: A Status Check